Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report) shot up 3.6% on Wednesday . The stock traded as high as $82.50 and last traded at $79.76. Approximately 1,243,617 shares were traded during mid-day trading, an increase of 557% from the average daily volume of 189,291 shares. The stock had previously closed at $77.01.
Gemini Therapeutics Stock Performance
The firm has a market capitalization of $3.42 billion, a PE ratio of -78.94 and a beta of -0.12. The firm has a fifty day moving average of $70.03 and a 200 day moving average of $70.05.
Gemini Therapeutics Company Profile
Gemini Therapeutics (NASDAQ:GMTX) is a clinical?stage biotechnology company focused on the discovery and development of integrin?targeting therapies for fibrotic diseases. Leveraging a proprietary antibody discovery platform, Gemini identifies and optimizes highly selective inhibitors of integrin subunits that play a key role in activating transforming growth factor?? (TGF-?), a central driver of tissue fibrosis. The company’s approach is designed to block fibrotic signaling at its source, potentially offering improved safety and efficacy profiles compared with broader anti?fibrotic agents.
Gemini’s lead programs are directed toward chronic kidney disease and idiopathic pulmonary fibrosis, two areas with significant unmet medical need and limited treatment options.
Read More
- Five stocks we like better than Gemini Therapeutics
- AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target
- Micron’s $250 Billion Bet Could Reshape the AI Memory Race
- Rocket Lab’s Stock Drop Comes With a Bullish Twist
- Amazon’s New Debt Deal Puts Its AI Spending Story on Trial
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
